miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer
Authors
Keywords
-
Journal
CANCER GENE THERAPY
Volume 25, Issue 3-4, Pages 68-76
Publisher
Springer Nature
Online
2018-01-05
DOI
10.1038/s41417-017-0005-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Perspectives of HER2-targeting in gastric and esophageal cancer
- (2017) James N Gerson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The EMT spectrum and therapeutic opportunities
- (2017) Dominic C. Voon et al. Molecular Oncology
- MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells
- (2017) Tao Jiang et al. ONCOLOGY REPORTS
- Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines
- (2017) Xin Wang et al. Oncotarget
- Targeted therapies for gastric cancer: failures and hopes from clinical trials
- (2017) Maria Apicella et al. Oncotarget
- Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease
- (2017) Manish A. Shah et al. Journal of the National Comprehensive Cancer Network
- An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
- (2016) G. Piro et al. CLINICAL CANCER RESEARCH
- Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer
- (2016) Chiara Arienti et al. Oncotarget
- Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
- (2015) Sharon T. Wilks BREAST
- Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer
- (2015) Adela Madrid-Paredes et al. BREAST CANCER RESEARCH AND TREATMENT
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
- (2015) C.-Y. Ock et al. CLINICAL CANCER RESEARCH
- HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases
- (2015) Rocco Cappellesso et al. HUMAN PATHOLOGY
- Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma
- (2015) DH Jensen et al. JOURNAL OF PATHOLOGY
- A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
- (2014) Carlos Gomez-Martín et al. CANCER LETTERS
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer
- (2014) Wen-Dong Bai et al. INTERNATIONAL JOURNAL OF CANCER
- LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53
- (2012) Xinliang Zhou et al. LIFE SCIENCES
- Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population
- (2012) Hasan Korkaya et al. MOLECULAR CELL
- HER2 Testing in Gastric Cancer
- (2010) Luca Albarello et al. ADVANCES IN ANATOMIC PATHOLOGY
- The role of the miR-200 family in epithelial-mesenchymal transition
- (2010) Perry S. Mongroo et al. CANCER BIOLOGY & THERAPY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Targeted HER2 Treatment in Advanced Gastric Cancer
- (2010) Jan Trøst Jørgensen ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started